Oncotype DX for Breast Cancer | Genomic Health, Inc.
Tailoring Treatment for Individual Patients with Early-Stage Breast Cancer
Oncotype DX® for Early-Stage, Invasive Breast Cancer
The company's lead product, the Oncotype DX breast cancer test, is the only multigene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage invasive breast cancer.
The test may benefit early-stage breast cancer patients whose cancer is:
- Oestrogen receptor positive (ER+). This means that the breast cancer expresses the oestrogen receptor and its growth is stimulated by the hormone oestrogen
- Lymph node negative (in pre- and post-menopausal patients). This means there that there are no cancer cells in the lymph glands
- Lymph node positive (in post-menopausal patients only)
- HER2 negative. This means that the cancer does not express high levels of the HER2 protein or have more than two copies of the HER2 gene.
The Oncotype DX test analyses the individual biology of a breast cancer tumour by examining the activity of 21 genes in the tumour tissue. The results of the analysis are fed into a formula that gives a number appearing in the Recurrence Score® report. This value – a number between 0 and 100 – can provide information about how likely breast cancer is to recur within 10 years of diagnosis and, perhaps more importantly, the likelihood that the patient will benefit from chemotherapy.
As the Oncotype DX test is performed on a small amount of the tissue removed during original surgery (core biopsy, lumpectomy, or mastectomy) this means the patient doesn’t need to undergo any additional surgery or procedure in order to have the test.
The Oncotype DX invasive breast cancer test has been available to patients in the UK since 2006.
Learn more about the Oncotype DX breast cancer test
Oncotype DX for DCIS (Ductal Carcinoma In Situ), Stage 0 Pre-Invasive Breast Cancer
In addition to the test for invasive breast cancer, the Oncotype DX test for DCIS is the first clinically validated genomic test to provide an individualised prediction of the 10-year risk of local recurrence (DCIS or invasive carcinoma) to help guide treatment decision-making for people diagnosed with ductal carcinoma in situ.
The Oncotype DX test for DCIS provides information in addition to standard measurements (such as margin width, tumour size and tumour grade) that doctors have traditionally used to estimate how likely a patient’s cancer is to return, and to help doctors and patients optimise treatment decisions.
For more information, please visit our U.S. website for Oncotype DX Breast DCIS Score